Baoji Pharmaceutical – B(02659.HK): Achieved revenue of 49.156 million yuan in 2025, a year-on-year increase of 700%

NightAirdropper

2026-03-27 16:10:41

Abstract generation in progress

Gelonghui March 26丨Baoji Pharmaceutical - B (02659.HK) announced that for the year ending December 31, 2025, it achieved revenue of RMB 49.156 million, a year-on-year increase of 700%; gross profit was RMB 43.751 million, a year-on-year increase of 772%; the loss attributable to the parent company was RMB 395 million, compared to a loss of RMB 364 million in the same period last year; basic and diluted loss per share was RMB 1.36.

Research and development expenses slightly decreased by 1.0% from RMB 250.7 million in 2024 to RMB 248.2 million in 2025. The decrease was mainly due to: (i) a reduction in share-based payment expenses related to equity incentives granted to the company’s R&D personnel by RMB 36.4 million, partially offset by (ii) an increase in trial and testing expenses by RMB 28.3 million as the company advanced the ongoing clinical development of candidate drugs and (iii) an increase in employee costs driven by the expansion of the R&D team by RMB 6.7 million.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.